Paid Clinical Trials Portland
Discover 165 paid clinical trials in Portland, Maine. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaThoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Sponsor:
Children's Oncology Group
Location:
Code:
NCT05235165
Conditions
Metastatic Malignant Neoplasm in the Lung
Metastatic Osteosarcoma
Osteosarcoma
Eligibility Criteria
Sex: All
Age: 0 - 50
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Questionnaire Administration
Thoracoscopy
Thoracotomy
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic LeukemiaFixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Sponsor:
Inhye Ahn
Location:
Code:
NCT06333262
Conditions
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pirtobrutinib
Obinutuzumab
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Sponsor:
Alexion Pharmaceuticals, Inc.
Location:
Code:
NCT06291376
Conditions
Immunoglobulin A Nephropathy
IgAN
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ravulizumab
Placebo
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisStudy to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Sponsor:
AbbVie
Location:
Code:
NCT05814627
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Adalimumab
Upadacitinib Matching Placebo
Adalimumab Matching Placebo
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast CancerOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Sponsor:
Stemline Therapeutics, Inc.
Location:
Code:
NCT05563220
Conditions
Breast Cancer
Metastatic Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Elacestrant
Alpelisib
Everolimus
Ribociclib
Palbociclib
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Sponsor:
Karyopharm Therapeutics Inc
Location:
Code:
NCT05611931
Conditions
Endometrial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Selinexor
Matching Placebo for selinexor
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Sponsor:
Genmab
Location:
Code:
NCT06191744
Conditions
Follicular Lymphoma (FL)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Epcoritamab
Prednisone
Rituximab
Lenalidomide
Doxorubicin
Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseaseColon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Sponsor:
NRG Oncology
Location:
Code:
NCT05174169
Conditions
Stage III Colon Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Signatera test
mFOLFOX6 3-6 month
CAPOX 3 month
mFOLFIRINOX
mFOLFOX6 6 month
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by SurgeryObservation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Sponsor:
NRG Oncology
Location:
Code:
NCT03180268
Conditions
Grade 2 Meningioma
Intracranial Meningioma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Clinical Observation
Intensity-Modulated Radiation Therapy
Laboratory Biomarker Analysis
Magnetic Resonance Imaging
Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to AutograftingSafety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting
Sponsor:
XenoTherapeutics, Inc.
Location:
Code:
NCT06223269
Conditions
Burns Degree Third
Burn (Disorder)
Burn Degree Second
Thermal Burn
Wound Heal
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Skin Xenotransplant
Autograft(ing)